januari
world
health
organ
declar
identif
chines
health
author
novel
coronaviru
classifi
new
viru
initi
emerg
chines
citi
wuhan
decemb
led
sharpli
spread
outbreak
human
respiratori
diseas
within
peopl
republ
china
sever
countri
worldwid
march
declar
global
pandem
current
itali
second
affect
countri
infect
china
first
autochthon
infect
case
confirm
itali
februari
march
case
death
regist
itali
consid
recent
evolut
italian
epidemiolog
pictur
mani
healthcar
facil
like
charg
manag
patient
affect
next
day
l
spallanzani
nation
institut
infecti
diseas
ircc
first
italian
hospit
admit
patient
affect
therefor
use
share
protocol
clinic
manag
confirm
case
appli
within
institut
order
support
facil
may
limit
experi
treat
patient
procedur
describ
present
document
appli
agreement
region
network
infecti
diseas
region
hospit
medic
specialti
network
activ
cooper
region
agenc
health
emerg
are
latter
charg
respons
territori
health
emerg
transport
patient
within
hospit
network
recommend
describ
within
document
base
limit
clinic
evid
consequ
consid
expert
opinion
may
modifi
accord
newli
produc
literatur
data
person
acut
respiratori
infect
defin
acut
onset
least
one
follow
signsymptom
fever
cough
respiratori
difficulti
breath
without
anoth
etiolog
complet
explain
clinic
present
histori
travelsstay
countri
document
local
transmiss
within
day
preced
symptom
onset
b
person
acut
respiratori
infect
histori
close
contact
probabl
confirm
case
within
day
preced
symptom
onset
c
person
sever
respiratori
infect
fever
least
one
signsymptom
respiratori
diseas
eg
cough
difficulti
breath
requir
hospit
admiss
anoth
etiolog
complet
explain
clinic
present
set
primari
carea
depart
countriesarea
autochthon
transmiss
observ
patient
singssymptom
acut
respiratori
infect
consid
suspect
case
accord
report
avail
http
wwwwhointemergenciesdiseas
suspect
case
result
real
time
pcr
perform
region
refer
laboratori
doubt
conclus
result
pancoronaviru
test
posit
person
laboratori
confirm
infect
perform
nation
refer
laboratori
istituto
superior
di
sanita
irrespect
clinic
sign
symptom
case
present
clinic
featur
suggest
complic
cours
infect
main
goal
clinic
manag
applic
strict
measur
infect
prevent
appli
patient
suspect
confirm
infect
regardless
clinic
sever
characterist
minim
addit
microbiolog
diagnost
clinic
monitor
virolog
monitor
diagnost
imag
antivir
therapi
support
therapi
individu
present
clinic
symptom
sign
consid
burden
clinic
symptom
higher
risk
complic
goal
clinic
manag
addit
one
state
asymptomat
patient
characterist
addit
microbiolog
diagnost
clinic
monitor
virolog
monitor
imag
diagnost
antivir
therapi
support
therapi
patient
present
sever
respiratori
condit
relat
infect
andor
complic
adjunct
goal
clinic
manag
stage
characterist
addit
microbiolog
diagnost
clinic
monitor
virolog
immunolog
biochem
monitor
imag
diagnost
antivir
therapi
support
therapi
patient
affect
sever
ill
due
sever
respiratori
failur
sever
impair
vital
function
main
goal
stage
conjunct
procedur
describ
unstabl
patient
characterist
addit
microbiolog
diagnost
clinic
monitor
virolog
immunolog
biochem
monitor
imag
diagnost
antivir
therapi
support
therapi
onset
new
worsen
respiratori
symptom
within
one
week
known
clinic
insult
chest
imag
radiograph
ct
scan
lung
ultrasound
bilater
opac
fulli
explain
effus
lobar
lung
collaps
nodul
origin
oedema
respiratori
failur
fulli
explain
cardiac
failur
fluid
overload
need
object
assess
eg
echocardiographi
exclud
hydrostat
caus
oedema
risk
factor
present
oxygen
adult
oxygen
children
note
oi
oxygen
index
osi
oxygen
index
use
postul
antivir
action
chloroquin
may
depend
sever
mechan
chang
cell
membran
ph
necessari
viral
fusion
interfer
glycosyl
viral
protein
hydroxychloroquin
analogu
chloroquin
prove
similar
better
invitro
efficaci
recent
studi
demonstr
invitro
efficaci
chloroquin
remdesivir
inhibit
replic
moreov
emerg
report
china
suggest
chloroquin
shown
superior
reduc
sever
durat
clinic
diseas
without
signific
advers
event
almost
one
hundr
patient
light
result
expert
consensu
group
china
recommend
chloroquin
treatment
recommend
dosag
sarscov
infect
chloroquin
mg
bid
hydroxychloroquin
mg
bid
day
combin
anoth
antivir
agent
lopinavirritonavir
remdesivir
seriou
advers
effect
may
includ
qt
prolong
torsad
de
point
reduct
seizur
threshold
anaphylaxi
anaphylactoid
reaction
neuromuscular
impair
neuropsychiatr
disord
potenti
increas
delirium
pancytopenia
neutropenia
thrombocytopenia
aplast
anemia
hepat
common
advers
reaction
nausea
vomit
diarrhea
abdomin
pain
visual
disturb
headach
extrapyramid
symptom
import
check
start
treatment
treatment
monitor
complet
blood
count
qt
interv
contraind
porphyria
defici
epilepsi
heart
failur
recent
myocardi
infarct
lopinavir
act
antivir
activ
inhibit
viral
replic
hiv
infect
ritonavir
act
boost
lopinavir
plasma
level
although
limit
anecdot
data
avail
clinic
efficaci
lopinavirritonavir
infect
far
seem
rapidli
reduc
replic
lopinavirritonavir
current
investig
within
sever
rct
china
recommend
dose
mg
bid
standard
dose
use
hiv
therapi
case
swallow
difficulti
unconsci
patient
oral
solut
lopinavirritonavir
administr
tablet
crush
seriou
advers
effect
may
includ
hypersensit
reaction
angioedema
stevensjohnson
syndrom
toxic
epiderm
necrolysi
ekg
alter
qt
prolong
torsad
de
point
av
block
pr
prolong
pancytopenia
pancreat
hepatotox
common
advers
reaction
gastrointestin
symptom
nauseavomit
diarrhea
monitor
transaminas
level
treatment
drugdrug
interact
treatment
start
light
possibl
shortag
lopinavirritonavir
stock
due
increas
prescript
suggest
possibl
use
darunavirritonavir
dosag
mg
ever
hour
replac
lopinavirritonavir
consid
similar
mechan
action
optim
safeti
profil
act
inhibit
viral
polymeras
recent
studi
explor
invitro
activ
remdesivir
chloroquin
demonstr
efficaci
drug
inhibit
replic
recent
case
report
describ
use
remdesivir
request
compassion
use
first
patient
unit
state
two
ongo
clinic
random
clinic
trial
china
evalu
remdesivir
moder
sever
infect
check
drugdrug
interact
antivir
therapi
pleas
visit
univers
liverpool
websit
http
tocilizumab
tcz
antihuman
receptor
monoclon
antibodi
inhibit
signal
transduct
bind
sil
main
approv
indic
rheumatoid
arthriti
associ
methotrex
us
food
drug
administr
approv
tcz
treatment
cytokin
releas
syndrom
cr
consist
system
inflammatori
respons
caus
massiv
releas
proinflammatori
cytokin
respons
iatrogen
eg
cart
therapi
infect
stimuli
although
lack
data
sarscov
pathogenesi
studi
china
show
possibl
correl
massiv
inflamm
sever
lung
damag
rapid
evolut
fatal
pneumonia
inde
patient
signific
differ
plasmat
level
observ
differ
stage
diseas
higher
express
sever
case
mild
one
moreov
biopsi
sampl
autopsi
sever
covid
patient
histolog
examin
show
diffus
alveolar
damag
cellular
fibromyxoid
exud
interstiti
mononuclear
inflammatori
infiltr
suggest
sever
immun
injuri
despit
lack
clinic
trial
tcz
efficaci
safeti
treatment
china
tcz
recent
approv
patient
affect
sever
pulmonari
complic
nation
health
commiss
peopl
republ
china
preliminari
data
observ
studi
conduct
china
sever
case
receiv
tcz
show
improv
clinic
radiolog
outcom
tcz
potenti
treatment
strategi
sever
critic
patient
particular
patient
could
benefit
tcz
therapi
although
optim
dose
schedul
tcz
treatment
cr
known
intend
posolog
mgkg
intraven
maximum
mgdose
infus
hour
addit
administr
evalu
basi
patient
respons
tcz
hour
apart
case
dosag
adjust
requir
relat
blood
paramet
liver
function
blood
count
accord
indic
specifi
patient
packag
insert
advis
monitor
follow
blood
paramet
full
blood
count
includ
platelet
count
altast
ldh
fibrinogen
ddimer
ferritin
creactiv
protein
differ
time
point
immedi
infus
immedi
infus
infus
infus
sever
lifethreaten
infect
alter
blood
paramet
alt
ast
uln
absolut
neutrophil
count
cellmmc
platelet
count
cellmmc
contraind
tcz
treatment
caution
requir
special
categori
pregnancybreastfeed
activ
latent
pulmonari
tuberculosi
bacterialfung
infect
immunerel
rheumat
diseas
concomit
therapi
antireject
drug
immunomodul
therapi
hepatopati
includ
viral
hepat
safeti
profil
tcz
well
known
tqt
studi
common
mark
laboratori
abnorm
low
neutrophil
count
decreas
observ
mean
neutrophil
count
follow
singl
dose
tcz
first
day
posttreat
reach
maximum
approxim
hour
infus
observ
incid
mark
decreas
neutrophil
count
increas
higher
dose
tcz
thrombocytopenia
increas
liver
function
test
also
describ
detail
inform
reader
refer
patient
packag
insert
abdeddaim
agrati
c
albarello
f
antinori
ascoli
bartoli
baldini
f
bellagamba
r
bevilacqua
n
biba
biava
g
boumi
e
busso
camici
capobianchi
mr
capon
caravella
cataldo
cerilli
chinello
g
cicalini
corpolongo
cristofaro
abramo
dantimi
c
de
ang
g
de
palo
mg
offizi
g
de
zotti
f
di
lorenzo
r
di
stefano
f
fusetti
galati
v
gagliardini
r
garotto
g
gebremeskel
tekl
saba
giancola
ml
giansant
f
girardi
e
goletti
granata
g
greci
mc
grilli
e
grisetti
gualano
g
iacomi
f
iannicelli
g
ippolito
g
lepor
l
liberton
r
lionetti
r
liuzzi
g
loiacono
l
macchion
marchioni
l
mariano
marini
mc
maritti
mastrobattista
mazzotta
v
mencarini
p
migliorisi
ramazzini
p
mondi
montalbano
mosti
murachelli
musso
nicastri
e
noto
p
oliva
palazzolo
c
palmieri
f
pareo
c
petron
pianura
e
pinnetti
c
pontarelli
puro
v
rianda
rosati
sampaolesi
santagata
c
scarcia
aprano
scarabello
v
scorzolini
l
stazi
gv
taibi
c
taglietti
f
tonnarini
r
topino
vergori
vincenzi
l
viscocomandini
u
vittozzi
p
zaccarelli
zaccaro
g
